Advertisement

Molecular screening of Smith–Lemli–Opitz syndrome in pregnant women from the Czech Republic

  • I. Blahakova
  • E. Makaturova
  • L. Kotrbova
  • M. Soukupova
  • J. Lastuvkova
  • L. Kozak
Original Article

Summary

Smith–Lemli–Opitz syndrome (SLOS) is an autosomal recessive metabolic disorder. SLOS is caused by the mutations in the gene for 3β-hydroxysterol Δ7 reductase (DHCR7; EC 1.3.1.21), which maps to chromosome 11q12-13. DHCR7 catalyses the final step in cholesterol biosynthesis—the reduction of 7-dehydrocholesterol to cholesterol. Clinical severity ranges from mild dysmorphism to severe congenital malformation and intrauterine lethality. Pregnant women are offered a biochemical screening test for Down syndrome in the second trimester, where the suspicion for SLOS could be registered, when the unconjugated estriol (uE3) level appears low. A group of 456 fetuses with a high risk for SLOS were examined by DNA analysis. We confirmed SLOS in 5 fetuses and 11 fetuses were carriers. One novel mutation (p.G30A) was detected. The most frequently found mutations, c.964-1> C and p.W151X, are also the most severe ones. At least one of these mutations was detected in each fetus with SLOS. This suggests that the biochemical screening of pregnant women probably uncovers mainly more severely affected fetuses. We confirmed SLOS also in two patients whose prenatal screening was negative. Both of them had nonsense mutation on one allele. It stands to reason that some modifying factors may play a role in the reduction of the uE3 level in the mother’s serum.

Keywords

Down Syndrome Maternal Serum Prenatal Screening Amniotic Fluid Cell Biochemical Screening 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Bradley LA, Canick JA, Palomaki GE, Haddow JE (1997) Undetectable maternal serum unconjugated estriol levels in the second trimester: risk of perinatal complications associated with placental sulfatase deficiency. Am J Obstet Gynecol 176(3): 531-35.CrossRefPubMedGoogle Scholar
  2. Bradley LA, Palomaki GE, Knight GJ, et al (1999) Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith–Lemli–Opitz (RSH) syndrome fetuses. Am J Med Genet 82(4): 355-58.CrossRefPubMedGoogle Scholar
  3. Bzduch V, Behulova D, Skoduva J (2000) Incidence of Smith–Lemli–Opitz syndrome in Slovakia. Am J Med Genet 90: 260.CrossRefPubMedGoogle Scholar
  4. Cooper MK, Wassif CA, Krakowiak PA, et al (2003) A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat Genet 33(4): 508-13.CrossRefPubMedGoogle Scholar
  5. Correa-Cerro LS and Porter FD (2005) 3β-hydroxysterol Δ7-reductase and the Smith–Lemli–Opitz syndrome. Mol Genet Metab 84: 112-26.CrossRefPubMedGoogle Scholar
  6. Craig WY, Haddow JE, Palomaki GE, et al (2006) Identifying Smith–Lemli–Opitz syndrome in conjunction with prenatal screening for Down syndrome. Prenat Diagn 26(9): 842-49.CrossRefPubMedGoogle Scholar
  7. Fitzky BU, Witsch-Baumgartner M, Erdel M, et al (1998) Mutations in the Δ7-sterolreductase gene in the patients with the Smith–Lemli–Opitz syndrome. Proc Natl Acad Sci 95: 8181-186.CrossRefPubMedGoogle Scholar
  8. Fitzky BU, Glossmann H, Utermann G, Moebius FF (1999) Molecular genetics of the Smith–Lemli–Opitz syndrome and postsqualen sterol metabolism. Curr Opin Lipidol 10(2): 123-31.CrossRefPubMedGoogle Scholar
  9. Glass IA, Lam RC, Chang T, Roitman E, Shapiro LJ, Shackleton CH (1998) Steroid sulphatase deficiency is the major cause of extremely low oestriol production at mid-pregnancy: a urinary steroid assay for the discrimination of steroid sulphatase deficiency from other causes. Prenat Diagn 18(8): 789-00.CrossRefPubMedGoogle Scholar
  10. Irons M, Elias ER, Tint GS, Batta AK (1993) Defective cholesterol biosynthesis in Smith–Lemli–Opitz syndrome. Lancet 341: 1414.CrossRefPubMedGoogle Scholar
  11. Kelley RI (1997) A new face for an old syndrome. Am J Med Genet 68: 251-56.CrossRefPubMedGoogle Scholar
  12. Kelley RI (1998) RSH/Smith–Lemli–Opitz syndrome: mutations and metabolic morphogenesis. Am J Hum Genet 63: 322-26.CrossRefPubMedGoogle Scholar
  13. Kozák L, Kuhrová V, Blaková M, et al (1995) Phenylketonuria mutations and their relation to RFLP haplotypes at the PAH locus in Czech PKU families. Hum Genet 96: 472-76.CrossRefPubMedGoogle Scholar
  14. Kozák L, Francová H, Hrabincová E, et al (2000) Smith–Lemli–Opitz syndrome: molecular-genetic analyses of ten families. J Inherit Metab Dis 23: 409-12.CrossRefPubMedGoogle Scholar
  15. Krakowiak PA, Nwokoro NA, Wassif CA, et al (2000) Mutation analysis and description of sixteen RSH/Smith–Lemli–Opitz syndrome patients: polymerase chain reaction-based assays to simplify genotyping. Am J Med Genet 94(3): 214-27.CrossRefPubMedGoogle Scholar
  16. Kratz LE and Kelley RI (1999) Prenatal diagnosis of the RSH/Smith–Lemli–Opitz syndrome. Am J Med Genet 82(5): 376-81.CrossRefPubMedGoogle Scholar
  17. Loeffler J, Utermann G, Witsch-Baumgartner M (2002) Molecular prenatal diagnosis of Smith–Lemli–Opitz syndrome is reliable and efficient. Prenat Diagn 22: 827-30.CrossRefPubMedGoogle Scholar
  18. Moebius FF, Fitzky BU, Lee JN, Paik Y-K, Glossmann H (1998) Molecular cloning and expression of the human delta 7-sterol reductase. Proc Natl Acad Sci USA 95: 1899-902.CrossRefPubMedGoogle Scholar
  19. Nowaczyk MJ and Waye JS (2001) The Smith–Lemli–Opitz syndrome: a novel metabolic way of understanding developmental biology, embryogenesis, and dysmorphology. Clin Genet 59(6): 375-86.CrossRefPubMedGoogle Scholar
  20. Palomaki GE, Knight GJ, McCarthy JE, Haddow JE, Donhowe JM (1999) Maternal serum screening for Down syndrome in the United States: a 1995 survey. Am J Obstet Gynecol 176(5): 1046-051.CrossRefGoogle Scholar
  21. Palomaki GE, Bradley LA, Knight GJ, Craig WY, Haddow JE (2002) Assigning risk for Smith–Lemli–Opitz syndrome as part of 2nd trimester screening for Down’s syndrome. J Med Screen 9(1): 43-4.CrossRefPubMedGoogle Scholar
  22. Porter FD (2000) RSH/Smith–Lemli–Opitz syndrome: a multiple congenital anomaly/mental retardation syndrome due to an inborn error of cholesterol biosynthesis. Mol Genet Metab 71(1–2): 163-74.CrossRefPubMedGoogle Scholar
  23. Porter JA, Young KE, Beachy PA (1996) Cholesterol modification of hedgehog signaling proteins in animal development. Science 274: 255-59.CrossRefPubMedGoogle Scholar
  24. Putnam AR, Szakacs JG, Opitz JM, Byrne JL (2005) Prenatal death in Smith–Lemli–Opitz/RSH syndrome. Am J Med Genet 138(1): 61-5.CrossRefPubMedGoogle Scholar
  25. Ryan AK, Bartlett K, Clayton P, et al (1998) Smith–Lemli–Opitz syndrome: a variable clinical and biochemical phenotype. J Med Genet 35: 558-65.CrossRefPubMedGoogle Scholar
  26. Smith DW, Lemli L, Opitz JM (1964) A newly recognized syndrome of multiple congenital anomalies. J Pediatr 64: 210-17.CrossRefPubMedGoogle Scholar
  27. Tint GS, Irons M, Elias ER, et al (1994) Defective cholesterol biosynthesis associated with the Smith–Lemli–Opitz syndrome. N Engl J Med 330: 107-13.CrossRefPubMedGoogle Scholar
  28. Tint GS, Salen G, Batta AK, et al (1995) Correlation of severity and outcome with plasma sterol levels in variants of the Smith–Lemli–Opitz syndrome. J Pediatr 127: 82-7.CrossRefPubMedGoogle Scholar
  29. Wassif CA, Maslen C, Kachilele-Linjewile S, et al (1998) Mutations in the human sterol delta7-reductase gene at 11q12-13 cause Smith–Lemli–Opitz syndome. Am J Hum Genet 63: 55-2.CrossRefPubMedGoogle Scholar
  30. Waterham HR and Wanders RJA (2000) Biochemical and genetic aspects of 7-dehydrocholesterol reductase and Smith–Lemli–Opitz syndrome. Biochim Biophys Acta 1529(1–2): 340-56.PubMedGoogle Scholar
  31. Witsch-Baumgartner M, Fitzky BU, Ogorelkova M, et al (2000) Mutational spectrum in the Delta7-sterol reductase gene and genotype-phenotype correlation in 84 patients with Smith–Lemli–Opitz syndrome. Am J Hum Genet 66(2): 402-12.CrossRefPubMedGoogle Scholar
  32. Witsch-Baumgartner M, Loffler J, Utermann G (2001a) Mutations in the human DHCR7 gene. Hum Mutat 17(3): 172-82.CrossRefPubMedGoogle Scholar
  33. Witsch-Baumgartner M, Ciara E, Loffler J, et al (2001b) Frequency gradients of DHCR7 mutations in patients with Smith–Lemli–Opitz syndrome in Europe: evidence for different origins of common mutations. Eur J Hum Genet 9(1): 45-0.CrossRefPubMedGoogle Scholar
  34. Yu H, Lee MH, Starck L, et al (2000) Spectrum of delta(7)-dehydrocholesterol reductase mutations in patients with the Smith–Lemli–Opitz (RSH) syndrome. Hum Mol Genet 9(9): 1385-391.CrossRefPubMedGoogle Scholar

Copyright information

© SSIEM and Springer 2007

Authors and Affiliations

  • I. Blahakova
    • 1
    • 4
  • E. Makaturova
    • 2
  • L. Kotrbova
    • 2
  • M. Soukupova
    • 3
  • J. Lastuvkova
    • 3
  • L. Kozak
    • 1
  1. 1.Center of Molecular Biology and Gene TherapyUniversity Hospital BrnoBrnoCzech Republic
  2. 2.Department of Medical GeneticsUniversity Hospital BrnoBrnoCzech Republic
  3. 3.Department of Medical GeneticsMasaryk HospitalÚstí nad LabemCzech Republic
  4. 4.Centrum molekulární biologie a genové terapieFakultní nemocnice BrnoBrnoCzech Republic

Personalised recommendations